ArticleCancer imaging : the official publication of the International Cancer Imaging Society2026
Habitat-based imaging and peritumoral radiomics on ultrasound images for predicting lymphovascular invasion in breast invasive ductal carcinoma: a two-center study.
Article in Cancer imaging : the official publication of the International Cancer Imaging Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
purposeThis study aimed to evaluate the feasibility of employing habitat-based radiomic distributions in ultrasound (US) images to quantitatively characterize intratumoral heterogeneity. It also explored the potential of this approach to predict lymphovascular invasion (LVI) in breast invasive ductal carcinoma (IDC) patients and to identify the optimal extent of multiple peritumoral regions.
methodsA total of 408 women diagnosed with IDC from January 2020 to October 2023 were enrolled in this retrospective cohort study from two medical centers. Intratumoral areas were partitioned into four distinct habitat areas using K-means cluster analysis, while peritumoral regions were expanded at increments of 2, 4, and 6 mm. Radiomic features were independently extracted from the intra- and peri-tumoral areas, and habitat subregions for developing predictive models. These models incorporated three machine learning classifiers: Random Forest, Extreme Gradient Boosting (XGBoost), and Support Vector Machine (SVM), respectively. We subsequently established an integrated model encompassing intra- and peri-tumoral areas, and habitat radiomic features, and clinicopathological factors. The model performance was assessed through receiver operating characteristic (ROC), calibration curves, and decision curve analysis (DCA). Finally, SHapley Additive exPlanations (SHAP) and nonogram were applied to enhance model interpretability.
resultsThe Random Forest model exhibited superior performance in terms of the area under the curve (AUC) values of 0.861 (95% CI: 0.809-0.912), 0.832 (95% CI: 0.746-0.919), and 0.810 (95% CI: 0.684-0.935) for the training, validation, and test sets, separately. Additionally, the peri-2 mm model surpassed the performance of the other models (peri-4 mm, peri-6 mm) in LVI prediction. The integrated model, encompassing peri-2 mm features, clinicopathological factors, and habitat models, achieved robust predictive performance with AUC values of 0.940 (95% CI: 0.907-0.973), 0.924 (95% CI: 0.875-0.973), and 0.852 (95% CI: 0.732-0.972) for each respective set.
conclusionThe integrated model yields the improved predictive performance in predicting LVI status, and the model offer a reliable and feasible preoperative prediction method to enhance the clinical management and therapeutic planning for IDC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.